ProfileGDS5678 / 1433643_at
TitleAnti-VEGF and Anti-Notch treatment effect on U87 glioblastoma xenograft tumors [Mouse430_2]
OrganismMus musculus


control bevacizumab dibenzazepine GSM967852 GSM967853 GSM967854 GSM967855 GSM967856 GSM967862 GSM967863 GSM967864 GSM967865 GSM967857 GSM967858 GSM967859 GSM967860 GSM967861 23% 26% 70% 26% 24% 23% 22% 26% 25% 25% 23% 24% 24% 23% sort by agent Gene Expression Profile
Graph caption help
SampleTitleValueRank
GSM967852U87-EV human glioblastoma xenograft - Control 12.5768623
GSM967853U87-EV human glioblastoma xenograft - Control 22.5932826
GSM967854U87-EV human glioblastoma xenograft - Control 34.4091170
GSM967855U87-EV human glioblastoma xenograft - Control 42.5577826
GSM967856U87-EV human glioblastoma xenograft - Control 52.5096424
GSM967862U87-EV human glioblastoma xenograft - Bevacizumab treated 12.6047223
GSM967863U87-EV human glioblastoma xenograft - Bevacizumab treated 22.5588422
GSM967864U87-EV human glioblastoma xenograft - Bevacizumab treated 32.5871426
GSM967865U87-EV human glioblastoma xenograft - Bevacizumab treated 42.5527425
GSM967857U87-EV human glioblastoma xenograft - dibenzazepine treated 12.5586725
GSM967858U87-EV human glioblastoma xenograft - dibenzazepine treated 22.5281923
GSM967859U87-EV human glioblastoma xenograft - dibenzazepine treated 32.537824
GSM967860U87-EV human glioblastoma xenograft - dibenzazepine treated 42.5548124
GSM967861U87-EV human glioblastoma xenograft - dibenzazepine treated 52.5388223